EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

Musaddique Hussain, Gang Liu iD

Cells · 23.02.2024 · 13 (5) · 384

DOI: 10.3390/cells13050384 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 23.02.2024. Verfasst von Musaddique Hussain und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Asthma. Die Arbeit wurde bisher 128-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a prevalent chronic non-communicable disease, affecting approximately 300 million people worldwide. It is characterized by significant airway inflammation, hyperresponsiveness, obstruction, and remodeling. Eosinophilic asthma, a subtype of asthma, involves the accumulation of eosinophils in the airways. These eosinophils release mediators and cytokines, contributing to severe airway inflammation and tissue damage. Emerging evidence suggests that targeting eosinophils could reduce airway remodeling and slow the progression of asthma. To achieve this, it is essential to understand the immunopathology of asthma, identify specific eosinophil-associated biomarkers, and categorize patients more accurately based on the clinical characteristics (phenotypes) and underlying pathobiological mechanisms (endotypes). This review delves into the role of eosinophils in exacerbating severe asthma, exploring various phenotypes and endotypes, as well as biomarkers. It also examines the current and emerging biological agents that target eosinophils in eosinophilic asthma. By focusing on these aspects, both researchers and clinicians can advance the development of targeted therapies to combat eosinophilic pathology in severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaHumansEosinophilsInflammationCytokinesBiomarkers

Stichwörter der Autor:innen

asthmabiomarkerseosinophileosinophilic asthmainflammationinterleukins

Substanzen

CytokinesBiomarkers

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

ORCID-Profile: Gang Liu

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIH

Zitieren

APA

Hussain, M., & Liu, G. (2024). Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons. Cells, 13(5), 384. https://doi.org/10.3390/cells13050384

Vancouver

Hussain M, Liu G. Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons. Cells. 2024;13(5):384. doi:10.3390/cells13050384

BibTeX
@article{Hussain2024,
  author = {Hussain, Musaddique and Liu, Gang},
  title = {Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {5},
  pages = {384},
  doi = {10.3390/cells13050384}
}
Kostenlos starten →